Pregnane X Receptor

Pregnane X Receptor
Name	Pregnane X Receptor
Other names	PXR
Uniprot	PDB: ligand-binding domain structures available
Organism	Homo sapiens

Pregnane X Receptor Pregnane X Receptor is a nuclear receptor involved in xenobiotic sensing and regulation of genes linked to metabolism. It functions as a ligand-activated transcription factor that coordinates responses to diverse chemicals across tissues. Discovered through studies of drug metabolism, it has been explored by researchers at institutions and programs worldwide.

Introduction

Pregnane X Receptor emerged from parallel efforts in pharmacology, molecular biology, and toxicology at laboratories associated with National Institutes of Health, Massachusetts Institute of Technology, University of Cambridge, Salk Institute, Cold Spring Harbor Laboratory, Harvard University, and Stanford University. Early characterizations were reported in journals connected to editorial boards of Nature, Science, Cell Press, Proceedings of the National Academy of Sciences, and Journal of Biological Chemistry. Influential investigators linked PXR activity to clinical observations from studies at Mayo Clinic, Cleveland Clinic, Johns Hopkins University, Memorial Sloan Kettering Cancer Center, and pharmaceutical research at Pfizer, GlaxoSmithKline, Roche, Novartis, and Merck & Co..

Structure and Molecular Biology

The receptor is encoded by the NR1I2 gene studied in genomic projects such as the Human Genome Project, ENCODE Project, and analyses by groups at Wellcome Trust Sanger Institute and European Bioinformatics Institute. Structural biology contributions include crystallography efforts at European Molecular Biology Laboratory and the Protein Data Bank. Domain organization recalls motifs characterized in studies from Cold Spring Harbor Laboratory and Max Planck Society investigators. Coregulator interactions have been probed with techniques developed at Broad Institute, Karolinska Institutet, Weizmann Institute of Science, Riken, and Howard Hughes Medical Institute. Signal transduction themes align with findings from research networks including Human Protein Atlas and databases maintained by UniProt and NCBI.

Ligands and Activation Mechanisms

Ligand screening campaigns were undertaken by teams at pharmaceutical companies like AstraZeneca and Bristol-Myers Squibb, and academic groups at University of California, San Francisco, Yale University, University of Tokyo, Peking University, and University of Oxford. Endogenous and exogenous ligands implicated include steroids, bile acids, antibiotics, anticonvulsants, and herbal constituents examined in clinical contexts by World Health Organization collaborations. High-throughput assays developed at EMBL-EBI and Scripps Research have characterized agonists and antagonists; mechanistic insights paralleled discoveries from laboratories at Columbia University, University of Pennsylvania, Imperial College London, McGill University, and University of Toronto.

Physiological Roles and Tissue Expression

Expression profiling efforts by Genentech, Baylor College of Medicine, Vanderbilt University Medical Center, and consortia such as the GTEx Project have mapped receptor distribution in liver, intestine, kidney, and brain. Physiological themes intersect with metabolism and homeostasis studies from Dana-Farber Cancer Institute, Fred Hutchinson Cancer Center, Karolinska Institutet, University of Melbourne, and Monash University. Crosstalk with pathways investigated at Johns Hopkins Bloomberg School of Public Health and London School of Hygiene & Tropical Medicine relates to lipid handling, bile acid regulation, and interactions in inflammatory settings explored by researchers at Pasteur Institute, Karolinska Institutet, and Institut Curie.

Pharmacological and Toxicological Implications

Clinical pharmacology groups at FDA, European Medicines Agency, Pharmacia, and Eli Lilly and Company have integrated receptor activity into drug–drug interaction assessments. Toxicology studies appeared in collaborations involving National Toxicology Program, Environmental Protection Agency, Centers for Disease Control and Prevention, and environmental health centers at University of California, Berkeley and Johns Hopkins University. Activities of industrial chemicals and traditional medicines were evaluated by investigators at Beckman Coulter, AbbVie, Takeda Pharmaceutical Company, and research teams at Seoul National University, University of São Paulo, and Indian Council of Medical Research.

Clinical Significance and Therapeutic Targeting

Clinical trials and translational research involving PXR modulation have been registered through networks coordinated by ClinicalTrials.gov, with contributions from academic medical centers such as Mount Sinai Health System, UCLA Health, Duke University School of Medicine, University College London Hospitals, and Royal Marsden Hospital. Genetic polymorphism studies linked to variable drug response were performed at Mayo Clinic, Rigshospitalet, KU Leuven, University of Helsinki, and Osaka University. Drug discovery programs leveraging structure-based design came from collaborations among ExxonMobil Biomedical Sciences Institute-supported groups, biotechnology firms, and academic spinouts from ETH Zurich, University of Basel, and Technische Universität München.

Category:Nuclear receptors